24/7 Market News Snapshot 08 January, 2025 – Compass Therapeutics, Inc. Common Stock (NASDAQ:CMPX)

January 8, 2025

DENVER, Colo., 08 January, 2025 (247marketnews.com) – (Nasdaq:CMPX) are discussed in this article.
Compass Therapeutics, Inc. (Nasdaq:CMPX), a prominent clinical-stage biopharmaceutical company focused on antibody-based therapies for oncology, has recently experienced a notable surge in market activity. Following its opening price of $1.60, CMPX has jumped to $1.78, showcasing a remarkable 24.48% increase from the previous day’s close of $1.43, driven by strong investor interest highlighted by a trading volume of 1.19 million shares.

This enthusiasm comes as the company gears up for significant milestones in 2025. Compass is projected to announce top-line data from its Phase 2/3 trial of tovecimig, a bispecific antibody targeting DLL4 and VEGF-A, by the end of the first quarter of 2025. This vital trial is focused on patients suffering from advanced biliary tract cancer (BTC), underscoring the company’s commitment to addressing challenging oncology indications.

Additionally, Compass is excited to unveil CTX-10726, another bispecific antibody that targets PD-1 and VEGF-A, currently in preclinical development. The company plans to submit an Investigational New Drug (IND) application by year-end 2025, with initial proof-of-concept data anticipated in 2026. This strategic development aligns with Compass’s broader goal of leveraging expertise in angiogenesis and immuno-oncology.

To further strengthen its position, Compass is set to launch two Phase 2 biomarker trials in mid-2025, examining the efficacy of tovecimig in DLL4-positive colorectal cancer and CTX-471 in tumors expressing NCAM/CD56. Furthermore, the third dosing cohort of the Phase 1 trial for CTX-8371, a PD-1 x PD-L1 bispecific antibody, is fully enrolled, with preliminary data expected in late 2025.

With an estimated $127 million in cash and marketable securities anticipated at the end of 2024, Compass Therapeutics is well-positioned to maintain its operational momentum into the first quarter of 2027. The company remains steadfast in its mission to revolutionize oncology by delivering innovative treatments tailored to meet the needs of patients.

Related news for (CMPX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.